Mineralys Therapeutics, Inc.
- MLYS
- NASDAQ
- Biotechnology
- Aldosterone Synthesis Inhibitors
- Cardiovascular Drug Development
$20.60
Today +1.48%Quote Oct 19, 2026, 03:24 PM UTC
−27.45%over the last month
Max drawdown −31.0%From 1-month high −31.0%3 months −24.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.82B
Quote Oct 19
Next earnings
Nov 9
Expected, not confirmed
Analyst target
$29.00
+40.8% from here
Floor
$20.40
1.0% below price
Where the price sits
No analyst target range for this stock.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about MLYSPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
76